Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
Date:7/30/2008

DETROIT, July 30 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced today, that it has launched divalproex sodium delayed release tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma). Sun Pharma recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Depakote(R) delayed release tablets.

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches. These generic versions of divalproex sodium delayed release 125 mg, 250 mg, and 500 mg (valproic acid activity) tablets are bioequivalent to Depakote(R) delayed release tablets distributed by Abbott Laboratories. According to IMS Data, Depakote(R) had US. sales of approximately $750 million for the 12-month period ended March 2008.

Depakote(R) is a registered trademark of Abbott Laboratories.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
3. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
4. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
5. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
6. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud to ... Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment ... to address the limitations of fatigue monitoring technologies within the mining industry. Today ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... taught by healthcare management and evaluation leaders with decades of experience who remain ... in the United States healthcare system, there is a renewed demand for versatile, ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
(Date:1/23/2017)... ... 23, 2017 , ... Steviva Ingredients, makers of all-natural sweeteners ... National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... handling systems to complement our current rigorous food-safety management systems,” said Yishu Hou, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... partnership with the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia ... Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Jan. 20, 2017 ResMed (NYSE: RMD ), ... Winter Haven, Florida ) today announced they have agreed ... and 3B will be permitted to sell their existing products in ... one-time settlement payment to 3B to close the Florida ... include an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... Jan. 20, 2017  Faruqi & Faruqi, LLP, a leading ... or the "Company") (NASDAQ: KMPH ) of the ... certain officers and directors and underwriters of the Company,s April ... role of lead plaintiff. The lawsuit has been ... for Johnson County on behalf of ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: